These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22826519)

  • 21. Parameter identification and sedative sensitivity analysis of an agitation-sedation model.
    Rudge AD; Chase JG; Shaw GM; Lee D; Hann CE
    Comput Methods Programs Biomed; 2006 Sep; 83(3):211-21. PubMed ID: 16934360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Midazolam--how safe is it in sedation of newborn?].
    Gulczyńska E
    Pol Merkur Lekarski; 2005 Dec; 19(114):816-8. PubMed ID: 16521431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Midazolam in children. Alternative routes of administration].
    Saltanov AI; Barkhudarova NCh; Illarionov IuV; Matinian NV; Ordukhanian ZS
    Anesteziol Reanimatol; 2007; (1):66-70. PubMed ID: 17460996
    [No Abstract]   [Full Text] [Related]  

  • 25. Predicting the Best Fit: A Comparison of Response Surface Models for Midazolam and Alfentanil Sedation in Procedures With Varying Stimulation.
    Liou JY; Ting CK; Mandell MS; Chang KY; Teng WN; Huang YY; Tsou MY
    Anesth Analg; 2016 Aug; 123(2):299-308. PubMed ID: 27192475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats.
    Vuppugalla R; Zhang Y; Chang S; Rodrigues AD; Marathe PH
    Xenobiotica; 2012 Nov; 42(11):1058-68. PubMed ID: 22574883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans.
    Gudmundsdottir H; Sigurjonsdottir JF; Masson M; Fjalldal O; Stefansson E; Loftsson T
    Pharmazie; 2001 Dec; 56(12):963-6. PubMed ID: 11802661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
    Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of midazolam in critically ill pediatric patients.
    Nahara MC; McMorrow J; Jones PR; Anglin D; Rosenberg R
    Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):219-21. PubMed ID: 11420893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.
    Boulieu R; Lehmann B; Salord F; Fisher C; Morlet D
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):255-8. PubMed ID: 9725490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral midazolam-grapefruit juice drug interaction.
    Goho C
    Pediatr Dent; 2001; 23(4):365-6. PubMed ID: 11572503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intranasal and buccal midazolam in the treatment of acute seizures].
    Armijo JA; Herranz JL; Pena Pardo MA; Adín J
    Rev Neurol; 2004 Mar 1-15; 38(5):458-68. PubMed ID: 15029526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction.
    Platten HP; Schweizer E; Dilger K; Mikus G; Klotz U
    Clin Pharmacol Ther; 1998 May; 63(5):552-60. PubMed ID: 9630828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.
    Aoyama T; Hirata K; Yamamoto Y; Yokota H; Hayashi H; Aoyama Y; Matsumoto Y
    J Clin Pharm Ther; 2016 Aug; 41(4):392-8. PubMed ID: 27178380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sedative-hypnotics are widely abused by drivers apprehended for driving under the influence of drugs.
    Kriikku P; Hurme H; Wilhelm L; Rintatalo J; Hurme J; Kramer J; Ojanperä I
    Ther Drug Monit; 2015 Jun; 37(3):339-46. PubMed ID: 25254415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents.
    van Rongen A; Vaughns JD; Moorthy GS; Barrett JS; Knibbe CA; van den Anker JN
    Br J Clin Pharmacol; 2015 Nov; 80(5):1185-96. PubMed ID: 26044579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benzodiazepine hypnotics: sorting the pharmacokinetic facts.
    Greenblatt DJ
    J Clin Psychiatry; 1991 Sep; 52 Suppl():4-10. PubMed ID: 1680125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anesthesia considerations in West syndrome].
    Delás Ramírez F; Navarro Egea M; Pardina Badia B
    Rev Esp Anestesiol Reanim; 2000 Dec; 47(10):493-4. PubMed ID: 11212406
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.
    Zimmermann T; Yeates RA; Laufen H; Scharpf F; Leitold M; Wildfeuer A
    Arzneimittelforschung; 1996 Feb; 46(2):213-7. PubMed ID: 8720318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Useful information about the pharmacokinetics and pharmacodynamics of midazolam and lorazepam.
    Deem S
    Anesthesiology; 2002 Aug; 97(2):522; author reply 522-3. PubMed ID: 12151951
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.